论文部分内容阅读
目的分析中国全球基金耐多药肺结核项目患者治疗情况,为制定适合我国国情的耐多药肺结核患者治疗策略提供参考依据。方法通过项目月报表、季报表和专题收集耐多药肺结核患者治疗及痰菌阴转数据,分析患者纳入治疗情况、标准化治疗方案使用情况和6月末痰菌阴转情况。结果 1157例确诊耐多药肺结核患者,仅700例(60.5%)患者纳入抗结核药物化学治疗;收集治疗方案的473例患者中,433例(91.5%)患者使用标准化治疗方案;259例完成6个月治疗的患者中,6月末痰涂片和痰培养阴转率分别为79.4%和78.6%。结论确诊耐多药肺结核患者纳入治疗比例偏低,大部分患者能够接受二线抗结核药物组成的标准化治疗方案,并取得较好的初步治疗效果。
Objective To analyze the treatment of patients with MDR-TB in China Global Fund to provide a reference for the development of treatment strategies for MDR-TB patients that are suitable for China’s national conditions. Methods According to the monthly, quarterly reports and special topics of the project, the data of MDR-TB treatment and sputum negative conversion data were collected to analyze the patients’ treatment, the standardization of treatment and the situation of sputum negative conversion at the end of June. Results Of the 1157 confirmed cases of MDR-TB patients, only 700 (60.5%) were included in the anti-TB drug chemotherapy; 433 (91.5%) of the 473 patients receiving the treatment regimen used standardized regimens; and 259 completed 6 Months of treatment in patients with sputum smear and sputum culture at the end of June negative conversion rates were 79.4% and 78.6%. Conclusions The proportion of confirmed MDR-TB patients is relatively low. Most of the patients are able to receive standardized treatment regimens of second-line anti-TB drugs and achieve better initial treatment results.